| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-80819 | |||
| BSA Free | NB100-507SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-23484SS | |||
| Azide and BSA Free | NBP2-81015 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-30333SS | |||
| Azide and BSA Free | NBP2-80738 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56583SS | |||
| Azide and BSA Free | NBP2-80872 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-245SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-515-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-1828SS | |||
| Azide and BSA Free | NBP2-80880 | |||
![Immunocytochemistry/Immunofluorescence: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Methanol-fixed MEF cells](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser536]-Antibody-Immunocytochemistry-Immunofluorescence-NB100-82088-img0009.jpg "Immunocytochemistry/Immunofluorescence: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Methanol-fixed MEF cells")
![Immunohistochemistry-Paraffin: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Paraffin-embedded human breast carcinoma tissue.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser536]-Antibody-Immunohistochemistry-Paraffin-NB100-82088-img0007.jpg)
![Immunohistochemistry-Paraffin: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Paraffin-embedded human Lung carcinoma tissue](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser536]-Antibody-Immunohistochemistry-Paraffin-NB100-82088-img0008.jpg)
![Western Blot: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Western Blot analysis of various cells using NB100-82088 diluted at 1:2000](http://images.novusbio.com/fullsize/nb100-82088_rabbit-polyclonal-rela-nfkb-p65-p-ser536-antibody-23420241545352.jpg)
![Immunocytochemistry/ Immunofluorescence: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Immunofluorescence staining of methanol-fixed Hela cells using NB100-82088.](http://images.novusbio.com/fullsize/nb100-82088_rabbit-polyclonal-rela-nfkb-p65-p-ser536-antibody-103202523464512.jpg)
![Immunohistochemistry-Paraffin: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Analysis of paraffin-embedded human breast carcinoma tissue using NB100-82088 incubated with blocking peptide (right)](http://images.novusbio.com/fullsize/nb100-82088_rabbit-polyclonal-rela-nfkb-p65-p-ser536-antibody-103202523464555.jpg)
![Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (5, 15 and 50 ug) from 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit antiP53 antibody used for WB at0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/p53-Antibody-Western-Blot-NB200-171-img0076.jpg "Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (5, 15 and 50 ug) from 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit antiP53 antibody used for WB at0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.")
![Immunohistochemistry-Paraffin: p53 Antibody [NB200-171] - FFPE section of human lung cancer Antibody: Affinity purified rabbit anti- p53 used at 1:5,000 (0.2ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/p53-Antibody-Immunohistochemistry-Paraffin-NB200-171-img0075.jpg)
![Flow Cytometry: p53 Antibody [NB200-171] - p53 in Jurkat Cells, fixed in 1.5% PFA, and permeabilized in 90% Methanol. 1 million cells were stained with 1.5 ug anti-KLH IgG control or anti-p53 NB200-171 and secondary FITC-conjugated goat anti-rabbit (in a 150ul reaction). Black- anti-KLH control IgG; Red- anti-HDMX.](http://images.novusbio.com/fullsize/p53-Antibody-Flow-Cytometry-NB200-171-img0002.jpg)
![Chromatin Immunoprecipitation Sequencing: p53 Antibody [NB200-171] - Chromatin from MCF7 was immunoprecipitated with anti-p53 antibody and analyzed by DNA sequencing. The figure illustrates the peak distribution of p53 binding within a 250 Kb region of chromosome 6 as detected using anti-p53. ChIP-seq validation performed by Active Motif, Carlsbad, CA.](http://images.novusbio.com/fullsize/p53-Antibody-Chromatin-Immunoprecipitation-Sequencing-NB200-171-img0073.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (100 ug) from 293T cells that were treated with an siRNA for p53 (+) or mock treated (-). Antibody used at the indicated concentrations.](http://images.novusbio.com/fullsize/p53-Antibody-Western-Blot-NB200-171-img0003.jpg)
![Flow Cytometry: p53 Antibody [NB200-171] - Baseline p53 expression in human lymphocytes. Image from verified customer review.](http://images.novusbio.com/fullsize/p53-Antibody-Flow-Cytometry-NB200-171-img0004.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: p53 Antibody [NB200-171] - Detection of human P53 by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HEK293T cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-P53 antibody NB200-171 used for IP at 3 ug per reaction. P53 was also immunoprecipitated by rabbit anti-P53 antibody NB100-2204. For blotting immunoprecipitated P53, NB200-171 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/p53-Antibody-Immunoprecipitation-NB200-171-img0077.jpg)
![Immunocytochemistry/Immunofluorescence: KAT3B/p300 Antibody (RW128) [NB100-507] - HeLa cells were fixed in 4% paraformaldehyde for 10 min and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-KAT3B Antibody (RW128) at 5 ug/ml for 60 minutes at room temperature and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW128-Immunocytochemistry-Immunofluorescence-NB100-507-img0005.jpg "Immunocytochemistry/Immunofluorescence: KAT3B/p300 Antibody (RW128) [NB100-507] - HeLa cells were fixed in 4% paraformaldehyde for 10 min and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-KAT3B Antibody (RW128) at 5 ug/ml for 60 minutes at room temperature and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective.")
![Western Blot: KAT3B/p300 Antibody (RW128) [NB100-507] - Detection of p300 in a HeLa nuclear extract using NB100-507 (1:250). ECL: 15 sec exposure.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW128-Western-Blot-NB100-507-img0003.jpg)
![Flow (Intracellular): KAT3B/p300 Antibody (RW128) [NB100-507] - An intracellular stain was performed on THP-1 cells with KAT3B/p300 (RW128) antibody NB100-507 (blue) and a matched isotype control NBP2-27287 (orange). Cells were fixed with 4% PFA and permeabilized with 0.1% Saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW128-Flow-Intracellular-NB100-507-img0004.jpg)
![Western Blot: KAT3B/p300 Antibody (RW128) [NB100-507] - Western Blot: KAT3B/p300 Antibody (RW128) [NB100-507] - Kinase active Src is present in the nuclei of Panc-1 cells in association with p300. Subcellular fractionation and localization of Src and p300 in Panc-1 cells. Cell lysates of equal total protein or Panc-1 subcellular fractions were subjected to immunoblotting analysis for Src, pSrc, p300, tubulin (cytoskeletal proteins), GAPDH (soluble cytoplasmic proteins), calnexin (endoplasmic reticulum), grim19 (mitochondria), histone H3 (chromatin), and lamin A/C (nuclear lamina). Image collected and cropped by Citeab from the following publication (A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer. Oncotarget (2016) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW128-Western-Blot-NB100-507-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: KAT3B/p300 Antibody (RW128) [NB100-507] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-KAT3B/p300 Antibody (RW128) NB100-507 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW128-Immunocytochemistry-Immunofluorescence-NB100-507-img0009.jpg)
![Flow Cytometry: KAT3B/p300 Antibody (RW128) [NB100-507] - An intracellular stain was performed on Raw264.7 cells with KAT3B/p300 Antibody (RW128) NB100-507 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW128-Flow-Cytometry-NB100-507-img0010.jpg)
![Western Blot: KAT3B/p300 Antibody (RW128) [NB100-507] - Kinase active Src is present in the nuclei of Panc-1 cells in association with p300. Src and p300 co-association in Panc-1 cells. Immunoblotting analysis of Src or p300 immunecomplexes from Panc-1 nuclear isolates probing for Src or p300, or IgG control. Image collected and cropped by Citeab from the following publication (A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer. Oncotarget (2016) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW128-Western-Blot-NB100-507-img0006.jpg)
![Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - CAFs induced miR-33b downregulation and promoted the EMT phenotype in lung cancer cells. The protein expression levels of E-cadherin, Vimentin, ZEB1, Twist1 and Snail1 in the lung cancer cells co-cultured with CAFs were detected by immunoblotting, using GAPDH protein as the loading control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23082), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Western-Blot-NBP2-23484-img0014.jpg "<b>Biological Strategies Validation. </b>Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - CAFs induced miR-33b downregulation and promoted the EMT phenotype in lung cancer cells. The protein expression levels of E-cadherin, Vimentin, ZEB1, Twist1 and Snail1 in the lung cancer cells co-cultured with CAFs were detected by immunoblotting, using GAPDH protein as the loading control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23082), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: ZEB1 Antibody (2A8A6) [NBP2-23484] - ZEB1 antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunocytochemistry-Immunofluorescence-NBP2-23484-img0009.jpg)
![Immunohistochemistry: ZEB1 Antibody (2A8A6) [NBP2-23484] - IHC analysis of paraffin-embedded human cervical cancer tissues with DAB staining.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunohistochemistry-NBP2-23484-img0006.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on U-87 cells with ZEB1 [2A8A6] Antibody NBP2-23484AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0012.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - ZEB1 expression was assayed in lung adenocarcinoma cells after transfectionwith miR-33b or miR-NC, anti-miR-33b or anti-miR-NC in H1299 and A549 cells. Image submitted by verified customer review.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Western-Blot-NBP2-23484-img0013.jpg)
![Immunohistochemistry: ZEB1 Antibody (2A8A6) [NBP2-23484] - IHC analysis of paraffin-embedded human recturm cancer tissues with DAB staining.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunohistochemistry-NBP2-23484-img0004.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - Flow cytometric analysis of Hela cells using ZEB1 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0007.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on with A549 cells with ZEB1 Antibody NBP2-23484PE and a a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0010.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on Jurkat with ZEB1 Antibody (2A8A6) NBP2-23484 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Mouse F(ab)2 IgG (H+L) PE-conjugated Antibody (R&D Systems, F0102B)](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0011.jpg)
![Western Blot: Factor Inhibiting HIF-1 Antibody (162c) [NBP1-30333] - Analysis in A431 cell lysates using NBP1-30333.](http://images.novusbio.com/fullsize/Factor-Inhibiting-HIF-1-Antibody-162c-Western-Blot-NBP1-30333-img0006.jpg "Western Blot: Factor Inhibiting HIF-1 Antibody (162c) [NBP1-30333] - Analysis in A431 cell lysates using NBP1-30333.")
![Immunocytochemistry/Immunofluorescence: Factor Inhibiting HIF-1 Antibody (162c) [NBP1-30333] - FIH (162C) antibody was tested in A431 cells with FITC (green). Nuclei and alpha-tubulin were counterstained with Dapi (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/Factor-Inhibiting-HIF-1-Antibody-162c-Immunocytochemistry-Immunofluorescence-NBP1-30333-img0005.jpg)
![Immunohistochemistry: Factor Inhibiting HIF-1 Antibody (162c) [NBP1-30333] - Analysis of FIH in human renal cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/Factor-Inhibiting-HIF-1-Antibody-162c-Immunohistochemistry-NBP1-30333-img0007.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. Protein expression of Foxo1, Foxo3, and phospho-T24/32 Foxo1/3 in young (<3-month, n = 6), adult (3-18-month, n = 6), and old (18-20-month, n = 6) FVB/B6 mixed-strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean +/- SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t-test. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/acel.12701), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-614-img0014.jpg "Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. Protein expression of Foxo1, Foxo3, and phospho-T24/32 Foxo1/3 in young (<3-month, n = 6), adult (3-18-month, n = 6), and old (18-20-month, n = 6) FVB/B6 mixed-strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean +/- SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t-test. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/acel.12701), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: FOXO3 Antibody [NB100-614] - Analysis of FOXO3 in human B cell lymphoma using anti-FOXO3 antibody .Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunocytochemistry-Immunofluorescence-NB100-614-img0007.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NB100-614] - Sample: FFPE section of human ovarian carcinoma (left) and mouse renal cell carcinoma (right). Antibody: Affinity purified rabbit anti-FOXO3a used at a dilution of 1:1,000 (1ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-NB100-614-img0009.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: FOXO3 Antibody [NB100-614] - Detection of Human and Mouse FOXO3a by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa, 293T, Jurkat, mouse TCMK-1, and mouse NIH3T3 cells. Antibodies: Affinity purified rabbit anti-FOXO3a antibody NB100-614 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-614-img0011.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - FOXO3 Protein expression levels both control group and exercise group for skeletal muscles. Image submitted by a verified customer review *{Mouse WB}*](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-614-img0012.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: FOXO3 Antibody [NB100-614] - Detection of human FOXO3a by western blot of immunoprecipitates. Samples: Whole cell lysate (1 mg for IP; 20% of IP loaded) from MCF-7 cells. Antibodies: Affinity purified rabbit anti-FOXO3a antibody NB100-614 used for IP at 6 ug/mg lysate. FOXO3a was also immunoprecipitated by rabbit anti-FOXO3a antibody NB100-613. For blotting immunoprecipitated FOXO3a, NB100-614 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunoprecipitation-NB100-614-img0013.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. Representative Western blotting results. Foxo1- or Foxo1/3-specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM-cerebellum, STR-striatum, SCD-spinal cord, CTX-cortex, BST-brain stem, MDB-midbrain, HPC-hippocampus.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Knockout-Validated-NB100-614-img0015.jpg)
![Western Blot: Rabbit Polyclonal FOXO3 Antibody [NB100-614] - Analysis of FOXO3 and FOXM1in parental HCT-116 and HCT-116-FUR cells. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-614_rabbit-polyclonal-foxo3-antibody-western-blot-1652024104015.png)
![Western Blot: FOXO3 Antibody [NB100-614] - Increased proteotoxic stress & defective autophagy in Foxo1/3/4 knockout mice. (a) Tissue lysates from 12‐month‐old WT & KO brain cortex were analyzed by WB of indicated proteins. (c) p62 IF & (d) p62 & Ub IHC on cortical neurons from 12‐month‐old WT & KO brain cortex. Red arrows point to labeling positive inclusions. Scale bar = 200 μm. (e) Quantitation of representative results for (d). (f) Indicated genotype of neural progenitor cultures was differentiated into neurons for 5 days. Some cultures were treated with rapamycin (100 ng/ml) for 24 hr on day 4 of differentiation. (h) The autophagy activity was analyzed by flow cytometry. The bar graph shows autophagy indices as % of control of (f). (i) Cultures as in (f) were treated with chloroquine (100 ng/ml) for 4 hr & analyzed for the expression levels of LC3 by WB. Representative result from three to five independent experiments is shown. (b, g, j) Quantitation of WB band densities. Only chloroquine‐treated cultures were statistically compared in (j). Error bars, mean ± SEM. *p < .05. **p < .01, ***p < .005; ****p < .001. Statistical significance was determined by one‐way ANOVA Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-310202415541916.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-310202415535143.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-3102024155456.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Increased proteotoxic stress & defective autophagy in Foxo1/3/4 knockout mice. (a) Tissue lysates from 12‐month‐old WT & KO brain cortex were analyzed by WB of indicated proteins. (c) p62 IF & (d) p62 & Ub IHC on cortical neurons from 12‐month‐old WT & KO brain cortex. Red arrows point to labeling positive inclusions. Scale bar = 200 μm. (e) Quantitation of representative results for (d). (f) Indicated genotype of neural progenitor cultures was differentiated into neurons for 5 days. Some cultures were treated with rapamycin (100 ng/ml) for 24 hr on day 4 of differentiation. (h) The autophagy activity was analyzed by flow cytometry. The bar graph shows autophagy indices as % of control of (f). (i) Cultures as in (f) were treated with chloroquine (100 ng/ml) for 4 hr & analyzed for the expression levels of LC3 by WB. Representative result from three to five independent experiments is shown. (b, g, j) Quantitation of WB band densities. Only chloroquine‐treated cultures were statistically compared in (j). Error bars, mean ± SEM. *p < .05. **p < .01, ***p < .005; ****p < .001. Statistical significance was determined by one‐way ANOVA Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-3102024155375.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-310202415525289.jpg)
![Western Blot: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - Analysis of p50 in HeLa lysate in the A) absence and B) presence of immunizing peptide using p50 antibody at 5 ug/ml.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Western-Blot-NB100-56583-img0004.jpg "Western Blot: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - Analysis of p50 in HeLa lysate in the A) absence and B) presence of immunizing peptide using p50 antibody at 5 ug/ml.")
![Immunohistochemistry-Paraffin: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - IHC-P of rabbit aorta using NB100-56583. Secondary antibody: anti-mouse histofine ( Nisherei Bioscience Inc. ref: 414131F). Development: DAB (Dako ref: K346811-2) and counterstained with Hematoxylin. Submitted via verified customer review](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Immunohistochemistry-Paraffin-NB100-56583-img0009.jpg)
![Flow Cytometry: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - An intracellular stain was performed on U937 cells with NFkB p105/p50 [2J10D7] Antibody NB100-56583C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Flow-Cytometry-NB100-56583-img0008.jpg)
![Immunohistochemistry-Paraffin: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - analysis of human breast tumor tissue using an isotype control antibody (top) and p50 antibody (bottom) at 5 ug/ml.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Immunohistochemistry-Paraffin-NB100-56583-img0003.jpg)
![Flow Cytometry: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - An intracellular stain was performed on Jurkat cells with NFkB p105/p50 Antibody (2J10D7) NB100-56583C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes. Both antibodies were conjugated to Dylight 650.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Flow-Cytometry-NB100-56583-img0005.jpg)
![Flow Cytometry: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - An intracellular stain was performed on HeLa cells with NFkB p105/p50 Antibody (2J10D7) NB100-56583C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes. Both antibodies were conjugated to Dylight 650.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Flow-Cytometry-NB100-56583-img0006.jpg)
![Flow Cytometry: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - An intracellular stain was performed on U2-OS cells with NFkB p105/p50 [2J10D7] Antibody NB100-56583C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Flow-Cytometry-NB100-56583-img0007.jpg)
![Immunohistochemistry-Paraffin: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - Analysis of a FFPE tissue section of human lymph node using 1:200 dilution of NFkB p105/p50 (2J10D7) antibody. The staining was developed using HRP labeled anti-mouse secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/antibody/nb100-56583_mouse-monoclonal-nfkb-p105-p50-antibody-2j10d7-imgenex-img-5812a-2210202585646.jpg)
![Western Blot: RelA/NFkB p65 [p Ser529, p Ser536] Inhibitor Peptide Set [NBP2-29321] - Inhibits TNF-induced NF-kB activation: KBM-5 cells were incubated with various concentrations of peptides for 1 hr and treated with 0.1nM TNF for 30min. Nuclear extracts were prepared and NF-kB activation was analyzed by EMSA (Please refer toTakada et al, 2004 for further details). PTD-p65-P6 suppresses TNF-induced NF-kB activation by 25% at 100 uM and completely at 150 uM, where as the control peptide, PTD or p65-P6 without PTD did not have any effect.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser529--p-Ser536]-Inhibitor-Peptide-Set-Western-Blot-NBP2-29321-img0015.jpg "Western Blot: RelA/NFkB p65 [p Ser529, p Ser536] Inhibitor Peptide Set [NBP2-29321] - Inhibits TNF-induced NF-kB activation: KBM-5 cells were incubated with various concentrations of peptides for 1 hr and treated with 0.1nM TNF for 30min. Nuclear extracts were prepared and NF-kB activation was analyzed by EMSA (Please refer toTakada et al, 2004 for further details). PTD-p65-P6 suppresses TNF-induced NF-kB activation by 25% at 100 uM and completely at 150 uM, where as the control peptide, PTD or p65-P6 without PTD did not have any effect.")
![Western Blot: RelA/NFkB p65 [p Ser529, p Ser536] Inhibitor Peptide Set [NBP2-29321] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 (3) for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser529--p-Ser536]-Inhibitor-Peptide-Set-Western-Blot-NBP2-29321-img0013.jpg)
![Functional (Inhibition): RelA/NFkB p65 [p Ser529, p Ser536] Inhibitor Peptide Set [NBP2-29321] - TLR5/NF-kB/SEAPorter HEK 293 (NBP2-26277) cells were plated in 96-well plates at 5 x 10^4 cells/well for 16 h. Cells were preincubated with different concentrations (0, 1, 5, 10, 25 and 50 uM) of Inhibitory Peptide (NBP2-29321) and Control Peptide (NBP2-29334) for 1 h. Cells were then stimulated with 1 ng/ml Flagellin (NBP2-25289) for 24 h. Secreted alkaline phosphatase (SEAP) was analyzed using SEAPorter Assay Kit (NBP2-25285). *p < 0.05 versus control peptide at the corresponding concentrations (Mann-Whitney U test).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-p-Ser529-p-Ser536-Inhibitor-Peptide-Set-Functional-Inhibition-NBP2-29321-img0012.jpg)
![Western Blot: FoxP3 Antibody [NB600-242] - (1 ug/mL) staining of Human Muscle (A), (2 ug/mL) MOLT4 (B) and (1 ug/mL) negative control Pancreas (C) lysate (35 ug protein in RIPA buffer). Detected by chemiluminescence.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Western-Blot-NB600-242-img0010.jpg "Western Blot: FoxP3 Antibody [NB600-242] - (1 ug/mL) staining of Human Muscle (A), (2 ug/mL) MOLT4 (B) and (1 ug/mL) negative control Pancreas (C) lysate (35 ug protein in RIPA buffer). Detected by chemiluminescence.")
![Immunocytochemistry: FoxP3 Antibody [NB600-242] - (Treg) human blood cells gathered by cytospin and detected by FITC (A) and in phase contrast (B).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunocytochemistry-Immunofluorescence-NB600-242-img0008.jpg)
![Immunohistochemistry: FoxP3 Antibody [NB600-242] - (8ug/ml) staining of paraffin embedded Human Spleen. Heat induced antigen retrieval with citrate buffer Ph 6, HRP-staining.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-NB600-242-img0012.jpg)
![Flow Cytometry: FoxP3 Antibody [NB600-242] - Analysis of paraformaldehyde fixed Jurkat cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (4 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Flow-Cytometry-NB600-242-img0009.jpg)
![Immunofluorescence: FoxP3 Antibody [NB600-242] - Paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (4 ug/mL), showing strong localization to nucleoplasm. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (4 ug/mL).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunocytochemistry-Immunofluorescence-NB600-242-img0011.jpg)
![Control: FoxP3 Antibody [NB600-242] - Negative Control showing staining of paraffin embedded Human Spleen, with no primary antibody.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Control-NB600-242-img0013.jpg)
![Immunohistochemistry-Frozen: FoxP3 Antibody - BSA Free [NB600-245] - FoxP3 Antibody [NB600-245] - Healthy thymus from a C57BL/6 mouse stained with FoxP3 and CD4.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunocytochemistry-Immunofluorescence-NB600-245-img0013.jpg "Immunohistochemistry-Frozen: FoxP3 Antibody - BSA Free [NB600-245] - FoxP3 Antibody [NB600-245] - Healthy thymus from a C57BL/6 mouse stained with FoxP3 and CD4.")
![Immunohistochemistry-Frozen: FoxP3 Antibody - BSA Free [NB600-245] - FoxP3 Antibody [NB600-245] - Healthy thymus from a C57BL/6 mouse incubated only with CD4 and no Foxp3.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunocytochemistry-Immunofluorescence-NB600-245-img0012.jpg)
![Immunohistochemistry-Paraffin: FoxP3 Antibody [NB600-245] - Fox P3 was detected in immersion fixed paraffin-embedded sections of human tonsil using rabbit anti-human antibody (Catalog # NB600-245) at 1:100 dilution overnight at 4C. Tissue was stained using the VisuCyte anti-rabbit HRP polymer detection reagent (Catalog # VC003) with DAB chromogen (brown) and counterstained with hematoxylin (blue).Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-Paraffin-NB600-245-img0011.jpg)
![Western Blot: FOXP3 Antibody [NB600-245] - Detection of human FOXP3 using NB 600-245. Lane 1: Human CD4+CD25+ PBL, lane 2: HEK293T transfected with human Foxp3 cDNA, lane 3: 293/mouse foxp3, lane 4: 293/empty vector](http://images.novusbio.com/fullsize/FOXP3-Antibody-Western-Blot-NB600-245-img0009.jpg)
![Dual RNAscope ISH-IHC: FoxP3 Antibody [NB600-245] - CD8A mRNA (red) and FOXP3 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human breast cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-CD8A and FOXP3 antibody at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Dual-RNAscope-ISH-IHC-NB600-245-img0014.jpg)
![Dual RNAscope ISH-IHC: FoxP3 Antibody [NB600-245] - CD4 mRNA (red) and FOXP3 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human breast cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-CD4 and FOXP3 antibody at 1:200 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Dual-RNAscope-ISH-IHC-NB600-245-img0015.jpg)
![Western Blot: AHR Antibody (RPT9) [NB300-515] - Analysis of Aryl Hydrocarbon Receptor was performed by loading 20 ug of HEK293 lysate overexpressing Aryl Hydrocarbon Receptor (right lane B) or empty vector control (left lane A) and 10ul of PageRuler Plus Prestained Protein Ladder onto a 4-20% Tris-Glycine polyacrylamide gel.](http://images.novusbio.com/fullsize/AHR-Antibody-RPT9-Western-Blot-NB300-515-img0018.jpg "Western Blot: AHR Antibody (RPT9) [NB300-515] - Analysis of Aryl Hydrocarbon Receptor was performed by loading 20 ug of HEK293 lysate overexpressing Aryl Hydrocarbon Receptor (right lane B) or empty vector control (left lane A) and 10ul of PageRuler Plus Prestained Protein Ladder onto a 4-20% Tris-Glycine polyacrylamide gel.")
![Immunocytochemistry/Immunofluorescence: AHR Antibody (RPT9) [NB300-515] - Analysis of Aryl Hydrocarbon Receptor using Aryl Hydrocarbon Receptor Monoclonal Antibody (RPT9) shows staining in U251 Cells. Aryl Hydrocarbon Receptor (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing Aryl Hydrocarbon Receptor at a dilution of 1:20 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/AHR-Antibody-RPT9-Immunocytochemistry-NB300-515-img0010.jpg)
![Flow Cytometry: AHR Antibody (RPT9) [NB300-515] - Analysis of Aryl Hydrocarbon Receptor in NIH/3T3 cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/AHR-Antibody-RPT9-Flow-Cytometry-NB300-515-img0017.jpg)
![Western Blot: AHR Antibody (RPT9) [NB300-515] - Analysis of 40 ug of HEK293 lysate overexpressing Aryl Hydrocarbon Receptor (right lane) or empty vector control (left lane) and 10ul of PageRuler Prestained Protein Ladder.](http://images.novusbio.com/fullsize/AHR-Antibody-RPT9-Western-Blot-NB300-515-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody (RPT9) [NB300-515] - Analysis of Aryl Hydrocarbon Receptor using Aryl Hydrocarbon Receptor Monoclonal Antibody (RPT9) shows staining in A2058 Cells. Aryl Hydrocarbon Receptor (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing Aryl Hydrocarbon Receptor at a dilution of 1:20 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/AHR-Antibody-RPT9-Immunocytochemistry-NB300-515-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody (RPT9) [NB300-515] - Analysis of Aryl Hydrocarbon Receptor using Aryl Hydrocarbon Receptor Monoclonal Antibody (RPT9) shows staining in Hela Cells. Aryl Hydrocarbon Receptor (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing Aryl Hydrocarbon Receptor at a dilution of 1:20 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/AHR-Antibody-RPT9-Immunocytochemistry-NB300-515-img0009.jpg)
![Flow Cytometry: AHR Antibody (RPT9) [NB300-515] - Analysis of Aryl Hydrocarbon Receptor in Hela cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/AHR-Antibody-RPT9-Flow-Cytometry-NB300-515-img0012.jpg)
![Flow Cytometry: AHR Antibody (RPT9) [NB300-515] - Analysis of Aryl Hydrocarbon Receptor in PC-3 cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/AHR-Antibody-RPT9-Flow-Cytometry-NB300-515-img0016.jpg)
![Western Blot: NKX3.1 Antibody (0361) [NB100-1828] - Analysis of NKX3.1 in HeLa cell lysate using anti-NKX3.1 antibody. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/NKX3-1-Antibody-0361-Western-Blot-NB100-1828-img0006.jpg "Western Blot: NKX3.1 Antibody (0361) [NB100-1828] - Analysis of NKX3.1 in HeLa cell lysate using anti-NKX3.1 antibody. WB image submitted by a verified customer review.")
![Immunohistochemistry-Paraffin: NKX3.1 Antibody (0361) [NB100-1828] - Staining of human chondrosarcoma tissue with NKX3.1 monoclonal antibody. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/NKX3-1-Antibody-0361-Immunohistochemistry-Paraffin-NB100-1828-img0008.jpg)
![Western Blot: Nkx3.1 Antibody (0361) [NB100-1828] - Detection of NKX3.1 in mouse testis lysate using NB 100-1828. ECL detection 1 minute.](http://images.novusbio.com/fullsize/Nkx3-1-Antibody-0361-Western-Blot-NB100-1828-img0003.jpg)
![Immunohistochemistry-Paraffin: NKX3.1 Antibody (0361) [NB100-1828] - NKX3.1 was detected in immersion fixed paraffin-embedded sections of mouse testis using Mouse Anti-Mouse NKX3.1 (0361) Monoclonal Antibody (Catalog # NB100-1828) at 1:300 for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the nuclei in sperm cells.](http://images.novusbio.com/fullsize/NKX3-1-Antibody-0361-Immunohistochemistry-Paraffin-NB100-1828-img0007.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: NKX3.1 Antibody (0361) [NB100-1828] - DWB analysis of NKX3.1 expression in the indicated cells transfected with Ri-Vector (V-Ri) or shRNAs (Ri#1/2) against NKX3.1. Image collected and cropped by CiteAb from the following publication (//www.ncbi.nlm.nih.gov/pmc/articles/PMC6895605/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NKX3-1-Antibody-0361-Knockdown-Validated-NB100-1828-img0009.jpg)
![Western Blot: NKX3.1 Antibody (0361) - BSA Free [NB100-1828] - SALL2 transcriptionally upregulates ESR1 in breast cancerARNA‐seq analysis of ESR1 mRNA levels in 9 paired pre‐tamoxifen‐treated primary breast cancer tissues & relapsed tamoxifen‐resistant breast cancer tissues.BqRT–PCR analysis of ESR1 expression in 9 paired pre‐tamoxifen‐treated primary breast cancer tissues & relapsed tamoxifen‐resistant breast cancer tissues. GAPDH was used as an internal control.C, DWB analysis of SALL2 (A) & NKX3‐1 (B) expression in the indicated cells transfected with Ri‐Vector (V‐Ri) or shRNAs (Ri#1/2) against SALL2 or NKX3‐1. alpha ‐Tubulin was used as the loading control.E, FqRT–PCR analysis of ESR1 expression in the indicated cells transfected with Ri‐Vector or shRNAs (Ri#1/2) against SALL2 or NKX3‐1.Data information: In (A), P‐values were determined by two‐tailed paired Student's t‐test. In (B), data are presented as mean ± SD, & P‐values were determined by two‐tailed unpaired Student's t‐test, n = 3. In (E & F), data are presented as mean ± SD, & P‐values were determined by one‐way ANOVA test, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001, n.s., no significance. Exact P‐values are specified in Appendix Table S10.Source data are available online for this figure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31657150), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1828_mouse-monoclonal-nkx3-1-antibody-0361-310202415525249.jpg)